Novo Nordisk study highlight benefits of new type 2 diabetes therapy

Novo Nordisk has announced headline results from a new clinical study showing the effectiveness of semaglutide in the treatment of adults with type 2 diabetes.

The PIONEER 1 study represents the first phase IIIa trial investigating the efficacy and safety of the GLP-1 analogue compared with placebo in 703 people with type 2 diabetes, with a total of ten trials taking place as part of this study programme.

The primary objective of the study was achieved, with significant and superior improvements in long-term blood sugar levels observed for all three doses of oral semaglutide. Moreover, the 14 mg dose of oral semaglutide also demonstrated superior weight loss benefits.

More than 9,000 people with type 2 diabetes will be enrolled across the ten PIONEER clinical trials, all of which are expected to be completed in 2018.

Mads Krogsgaard Thomsen, executive vice-president and chief science officer of Novo Nordisk, said: "We look forward to providing data from the remaining nine PIONEER trials throughout this year and an expected regulatory submission in 2019."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.